Skip to main contentAI and Advanced
/
NURECA · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
NU
NSE · Equity shares · Medical Equipment & Supplies17.38 · -0.75%
Nureca NURECA
NSE:INR 310
BSE:INR 332
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for NURECA
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 292.62
Day rangeINR 326 — INR 345
52-week rangeINR 200.1 — INR 357
Volume32,252
Market cap310.6
P/E84.81
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)146.96
Net Income (INR Cr)2.08
Rev Growth (5 Year %)-7.19
EPS Growth (5 Year %)-46.1
P/E Ratio84.81
Book Value187.66
EPS2.13
Price/BV1.65Computed
Research path: Interpret Nureca's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
NURECANureca1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 196.16 | 209.98 | 205.17 |
| Accumulated Depreciation Total | -3.91 | -3.18 | -2.39 |
| Cash Equivalents | 0 | 0 | 12.75 |
| Other Liabilities Total | 0.79 | 0.7 | 0.98 |
| Accrued Expenses | 1.61 | 1.76 | 1.16 |
| Long Term Debt | 0.22 | 1.05 | 0.33 |
| Common Stock Total | 9.54 | 10 | 10 |
| Other Equity Total | -0.03 | -0.02 | -0.01 |
| Other Current Assets Total | 29.74 | 5.71 | 30.52 |
| Prepaid Expenses | 0.34 | 0.4 | 1.35 |
| Total Assets | 196.16 | 209.98 | 205.17 |
| Current Portof LT Debt/Capital Leases | 1.38 | 1.53 | 0.63 |
| Additional Paid-In Capital | 83.57 | 98.78 | 98.78 |
| Cash | 1.46 | 3.24 | 1.31 |
| Total Equity | 180.76 | 194.29 | 193.11 |
| Long Term Investments | 63.43 | 3.5 | Not available |
| Retained Earnings(Accumulated Deficit) | 87.68 | 85.53 | 84.34 |
| Total Common Shares Outstanding | 0.95 | 1 | 1 |
| Property/Plant/Equipment Total-Gross | 15.78 | 10.19 | 7.47 |
| Tangible Book Valueper Share Common Eq | 187.66 | 192.3 | 190.81 |
| Total Liabilities | 15.4 | 15.69 | 12.05 |
| Total Debt | 2.26 | 4.97 | 2.52 |
| Short Term Investments | 11.56 | 119.87 | 99.89 |
| Cashand Short Term Investments | 13.02 | 123.11 | 113.96 |
| Total Receivables Net | 22.32 | 18.15 | 15.14 |
| Notes Payable/Short Term Debt | 0.05 | 0.85 | 0.08 |
| Accounts Receivable-Trade Net | 8.8 | 3.32 | 1.61 |
| Property/Plant/Equipment Total-Net | 11.88 | 7.01 | 5.08 |
| Total Current Liabilities | 13.78 | 12.4 | 9.27 |
| Total Inventory | 49.26 | 42.58 | 31.63 |
| Accounts Payable | 5.08 | 6.56 | 5.17 |
| Other Currentliabilities Total | 5.66 | 1.71 | 2.23 |
| Total Long Term Debt | 0.83 | 2.59 | 1.81 |
| Intangibles Net | 1.7 | 1.98 | 2.3 |
| Other Long Term Assets Total | 3.71 | 4.09 | 5.19 |
| Note Receivable-Long Term | 0.76 | 3.44 | Not available |
| Total Current Assets | 114.68 | 189.95 | 192.59 |
| Capital Lease Obligations | 0.61 | 1.54 | 1.48 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-10.28
Margins
Operating Margin 12m-1.25
Operating Margin 5y Avg1.73
Net Profit Margin 12m1.42
Net Profit Margin 5y5.29
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio2.11
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk50.68
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Lenskart Solutions | INR 555.8 | 96,656.06 | 181 | — |
| Poly Medicure | INR 1,684.05 | 17,057.14 | 52.1 | — |
| Laxmi Dental | INR 217 | 1,196.47 | 35.63 | — |
| One Global Service Provider | INR 594 | 1,160.86 | 16.95 | — |
| Mallcom (India) | INR 1,033.2 | 642.08 | 21.91 | — |
Shareholding
Ownership
- Promoter
- 68.09%
- FII
- 0.11%
- MF
- 1.35%
- Other
- 31.80%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Nureca Consolidated March 2026 Net Sales at Rs 35.41 crore, up 11.55% Y-o-Y - Moneycontrol.comMarket news · 3 Jun 2026, 11:22 am
Nureca Consolidated March 2026 Net Sales at Rs 35.41 crore, up 11.55% Y-o-Y Moneycontrol.com
Nureca Ltd is Rated Strong Sell - Markets MojoMarket news · 3 Jun 2026, 8:05 am
Nureca Ltd is Rated Strong Sell Markets Mojo
Nureca Ltd Valuation Shifts Signal Heightened Risk Amid Market Downturn - Markets MojoMarket news · 2 Jun 2026, 8:38 am
Nureca Ltd Valuation Shifts Signal Heightened Risk Amid Market Downturn Markets Mojo
Nureca reports consolidated net loss of Rs 6.09 crore in the March 2026 quarter - Business StandardMarket news · 1 Jun 2026, 10:14 am
Nureca reports consolidated net loss of Rs 6.09 crore in the March 2026 quarter Business Standard
Nureca revises capex approval to ₹128 Cr for FY26 - scanx.tradeMarket news · 1 Jun 2026, 6:08 am
Nureca revises capex approval to ₹128 Cr for FY26 scanx.trade
Nureca Q4 FY26: Sharp Loss Reversal Raises Serious Concerns - Markets MojoMarket news · 31 May 2026, 5:03 pm
Nureca Q4 FY26: Sharp Loss Reversal Raises Serious Concerns Markets Mojo
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- board MeetingsTo consider other business matters.
- board MeetingsBuy Back of Shares
- board MeetingsBuy Back of Shares
- board MeetingsTo consider other business matters.
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Nureca
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Nureca Limited is a specialist in home healthcare and wellness products. Its products serve individuals, caregivers and medical practitioners across the globe. It offers a range of products specialized in home-based, non-invasive digital diagnosis and prevention of lifestyle diseases. Its range of products are spread across categories like respiratory wellbeing, physiotherapy, cardiac health monitoring, diabetes detection, mother and childcare and more. Its brands include Dr. Trust, trumom and Dr. Physio. Dr. Trust is a wellness and healthcare brand which provides medical devices and health monitoring solutions. trumom is a mother and childcare brand. Dr. Physio is an ortho and pain management brand. Its chronic devices include home monitoring devices and medical wearables that populate readings to identify health patterns. Its lifestyle products span weighing scales to yoga gear. Dr Trust 360 enables monitoring, analyses, storing and reporting of health data and patterns over time.
Company facts
- Industry
- Medical Equipment & Supplies
- Sector
- Medical Equipment & Supplies
- NSE Code
- NURECA
- BSE Code
- 543264
Questions
Stock FAQ
What is the symbol and ISIN of Nureca?
Nureca has the symbol NURECA and ISIN - INE0DSF01015.
What is the current price of Nureca?
Nureca is currently trading at INR 310.00.
What are the year high and year low of Nureca?
Nureca has a year high of INR 357.00 and a year low of INR 200.10.
What is the market capitalization of Nureca?
Nureca has a market capitalization of INR 310.60 crore.
What is the P/E ratio of Nureca?
Nureca has a P/E ratio of 84.81.
What is the dividend yield of Nureca?
Nureca has a dividend yield of 0.00%.
How is the financial performance of Nureca based on revenue, net income, and EPS?
Nureca has revenue of INR 146.96 crore, net income of INR 2.08 crore, and EPS of INR 2.44.
What is the book value of Nureca?
Nureca has a book value of INR 187.66.
What is the debt-to-equity ratio of Nureca?
Nureca has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Nureca?
Nureca has a price-to-book ratio of 1.65 and a price-to-sales ratio of 2.11.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.